Sep 2026 results: half-year revenue and net profit rise; German unit flagged

Emphasis Of MatterRevenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.5%Reaction day

₹1469.00

prior close

₹1510.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.7%-7.2% vs market

Pharmaceuticals peers, median of 173sector+2.0%-7.4% vs sector

On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 7.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

-0.8

15m

-2.5

30m

-2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.5+1.7-7.2+2.0-7.4

Next day

-9.1pendingpending+2.6-11.7

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The board approved unaudited standalone and consolidated results for the quarter and half-year ended 30 September 2026. Standalone half-year revenue rose 20.6% to Rs397.55 crore and net profit rose to Rs5.49 crore from Rs3.37 crore. Auditors did not qualify the results but highlighted Rs28.60 crore of funding to Venus Pharma GmbH awaiting share allotment. It faces financial difficulties and reported a Rs5.84 crore loss.

Likely market impact

Growth is positive, but the German unit's loss, pending share allotment and planned support raise recovery and execution risks for shareholders.